ライフサイエンスコーパス: debulk

1 tment interventions (predominantly localised debulking).

2 m-based chemotherapy and aggressive surgical debulking.

3 and in preventing recurrences after surgical debulking.

4 owth of metastatic tumor foci after surgical debulking.

5 initive tissue diagnosis, staging, and tumor debulking.

6 ard chemotherapy, immunotherapy, or surgical debulking.

7 s underwent stent implantation without prior debulking.

8 xtent of residual disease following surgical debulking.

9 ersist clinically after laparotomy and tumor debulking.

10 hemotherapy, radiation therapy, and surgical debulking.

11 tion of multimodal treatments after surgical debulking.

12 ypically involves complete local excision or debulking.

13 -type HGSOC) who underwent CT before primary debulking.

14 acryoadenitis who were managed with surgical debulking.

15 ary resection methods for utilizing FGS: (1) debulking, (2) wide local excision, and (3) whole organ

16 After ibrutinib lead-in tumor debulking, 36 of 40 patients (90%) with high tumor lysis

17 diagnosis (48%), are frequently incompletely debulked (44%) and demonstrate inferior survival; conver

18 ox isolation, 3 single ring isolation, and 1 debulking ablation) comprising 1643 patients (31.3% paro

19 edian survival time for women with optimally debulked adenocarcinoma of the ovary treated with intrav

20 y univariate analysis included partial mucin debulking, adenocarcinoma histology, systemic chemothera

21 ays after tumor inoculation) were surgically debulked and animals were treated with rofecoxib startin

22 ng of RASH3D19 is expected to lead to tumour debulking and alleviating resistance to KRAS inhibitors

23 OvCa patients initially respond to surgical debulking and chemotherapy, 75% of patients later succum

24 istically with radiotherapy to improve tumor debulking and control in preclinical models.

25 us CD20 expression, facilitating rapid tumor debulking and elimination of CD20-low/CD20- cells.

26 at the milli-spinner achieves ultrafast clot debulking and high-fidelity revascularization, outperfor

27 Surgical debulking and immunosuppressive agents such as rituximab

28 Debulking and incisional biopsies were performed, and th

29 t suitable for further CRS underwent radical debulking and intestinal transplantation at our centre.

30 grated approach provide both immediate tumor debulking and long-term protection against solid tumors,

31 h NSCLC were enrolled; 17 underwent complete debulking and PDT, three underwent partial debulking/PDT

32 ents with a complete clinical response after debulking and platinum-based chemotherapy: the five-year

33 with metastasis, advanced stage, suboptimal debulking and poor prognosis.

34 ministered enabled acute autochthonous tumor debulking and resulted in durable clinical remission.

35 y was to limit instrumentation to extraction debulking and to stabilizing the site with stent deploym

36 Debulking and trimming effectively managed all cases of

37 es with mucosal overgrowth underwent mucosal debulking and trimming.

38 The patient underwent tumor debulking, and osteosarcoma was confirmed with pathologi

39 erapy, postoperative patients after surgical debulking, and patients undergoing radiotherapy.

40 programmable pneumatic compression, surgical debulking, and physiologic procedures.

41 f treatment with ASHAP is an effective tumor debulking approach in patients previously treated with b

42 remains little attention on liposuction, or debulking, as an effective treatment option.

43 The majority of patients underwent surgical debulking, as well as treatment with glucocorticoids and

44 , after adjusting for age, stage and optimal debulking, ASC pro-collagen-1alpha and serum sLAIR-1 lev

45 py and radiotherapy after surgical biopsy or debulking at 4 US centers during 1998-2019.

46 review of consecutive patients who underwent debulking at our institution was conducted.

47 patients started treatment with bendamustine debulking before induction and maintenance treatment, wh

48 or adequate staging of nodal status or tumor debulking before secondary therapy.

49 most patients with SVG aortoostial lesions, debulking before stent implantation may not be necessary

50 However, the impact of debulking before stenting in this complex lesion subset

51 Debulking biopsy procedures for idiopathic dacryoadeniti

52 esion, 44 patients with 50 lesions underwent debulking by laser angioplasty, rotational or directiona

53 c herpes virus (oHSV) initiates direct tumor debulking by tumor lysis and activates anti-tumor immuni

54 ted for Y-redirected cells and enabled tumor debulking by tumor-redirected lymphocytes.

55 e tumor burden is not too large and complete debulking can be achieved, PDS is superior to NACT due t

56 gnosis of primary HGSC, followed by complete debulking, could improve survival, but its benefit in re

57 All patients received two debulking cycles of intravenous obinutuzumab, followed b

58 While this therapy is effective at rapidly debulking directly injected tumor masses, achieving comp

59 A chemotherapy strategy was used to debulk disease before administration of granulocyte colo

60 will address the same question in optimally debulked disease.

61 le uricases and those in the pipeline, their debulking effect and their outcomes related to gout and

62 us (IV) chemotherapy in women with optimally debulked epithelial ovarian cancer confined to the abdom

63 was evaluated in 139 advanced, suboptimally debulked epithelial ovarian cancer specimens from patien

64 uspected advanced ovarian cancer is surgical debulking followed by platinum-based chemotherapy.

65 ear clinical outcomes in patients undergoing debulking followed by stent implantation versus stenting

66 The benefits of debulking for bifurcation lesions were especially seen i

67 tients who underwent percutaneous vegetation debulking for tricuspid valve infective endocarditis fro

68 ess was 73% in the PTCA group and 97% in the debulking group (p = 0.01).

69 n the PTCA group as compared with 28% in the debulking group (p = 0.05).

70 wo patients in the PTCA group and one in the debulking group.

71 esions) underwent stent implantation without debulking (group II).

72 uited from non-UK centers who were similarly debulked (hazard ratio = 1.85; 95% CI, 1.16 to 2.97; P =

73 and obinutuzumab after optional bendamustine debulking in 45 patients with relapsed/refractory chroni

74 mpact of first-line, adjuvant treatments and debulking in advanced cancers.

75 ng for case selection rather than aggressive debulking in all patients irrespective of disease extent

76 a randomised trial that supported aggressive debulking in patients with MSCC.

77 obinutuzumab after an optional bendamustine debulking in patients with relapsed/refractory chronic l

78 oaches (perhaps in conjunction with surgical debulking) in human clinical trials of treatment of meso

79 nsists of surgical staging, operative tumour debulking including total abdominal hysterectomy and bil

80 (PMA) is an emerging acute intervention for debulking infective vegetations in right-sided infective

81 ormula: see text] 5 in daily fractions) with debulking intent, we suggest a personalized treatment st

82 In some other countries, debulking is a common procedure for the surgical treatme

83 d valve infective endocarditis, percutaneous debulking is a treatment option.

84 iac tumors indicates that a less risky tumor debulking is effective for a subset of histotypes such a

85 Percutaneous debulking is feasible, effective, and safe in treating p

86 ction of patients with a history of previous debulking), lack of invasive tumor growth, and minimal r

87 tocol should accomplish the following goals: debulk large tumors, release tumor antigen for cross-pre

88 ains the mainstay of treatment, and thrombus debulking, lead extraction, venoplasty, and stenting are

89 tients, who were more likely to be optimally debulked (< or = 2 cm residual disease) than UK patients

90 Surgical debulking may have a role in symptom control beyond that

91 few insurance companies offered coverage for debulking (n = 13, 19.4%) or physiologic (n = 5, 7.5%) p

92 Further, issues regarding the role of debulking nephrectomy, timing of therapy, and appropriat

93 m in diameter; (2) pneumatic dissection; (3) debulking of approximately 80% of the anterior stroma; (

94 , the potential for atraumatic and effective debulking of atheromatous plaque through a biological me

95 The monolithic CTC-iChip enables debulking of blood samples at 15-20 million cells per se

96 Seven patients had palliative debulking of cervical tumor.

97 ause it provides the most effective clinical debulking of hematologic malignancies, and because CSC-t

98 aging, we first showed quantitative surgical debulking of human GBM tumors in mice, which resulted in

99 tion of tumor cells remaining after surgical debulking of malignant brain tumors.

100 hermore, the model can suggest whether prior debulking of the tumor with chemo-immunotherapy can prol

101 ablation of localized earlystage tumors, or debulking of unresectable late-stage cancers.

102 ed the effect of plaque burden modification (debulking) on the short- and long-term clinical outcomes

103 nce of optimal debulking with regard to PFS (debulking optimal v suboptimal: HR, 0.51; 95% CI, 0.30 t

104 ancer patients obtained at standard surgical debulking or laparoscopic biopsy.

105 s from most oral virus re-infections through debulking or minimizing transmission to others.

106 Participants who underwent major debulking or total or near-total resection had longer ov

107 vor of cisplatin for patients with optimally debulked ovarian and limited-stage small-cell lung cance

108 latin were equally effective in suboptimally debulked ovarian cancer and extensive-stage small-cell l

109 en in 62 (45%) of the advanced, suboptimally debulked ovarian cancer patients.

110 2-year survival rate in women with optimally debulked ovarian cancer.

111 in in chemotherapy regimens for suboptimally debulked ovarian cancer.

112 constitute a standard therapy for optimally debulked ovarian cancer.

113 e of IP chemotherapy in women with optimally debulked ovarian cancer.

114 suboptimally (P = 0.0179) but not optimally debulked (P = 0.144) patients.

115 nificantly reduced the recurrence rate after debulking (P < 0.01).

116 For suboptimally debulked patients, confirmation of the predictive gene s

117 to therapeutic intervention in suboptimally debulked patients, pathway analysis was completed for th

118 have beneficial effects on PFS in optimally debulked patients.

119 Splenectomy may reverse AMR by debulking PCs.

120 e debulking and PDT, three underwent partial debulking/PDT, and two patients were unresectable.

121 ces for crossing chronic total occlusions or debulking plaque with atherectomy are less rigorously st

122 larization rates were the same (16.3% in the debulking plus stent group vs. 14.4% in the stent alone

123 sess the outcomes of percutaneous mechanical debulking (PMD) of lead-associated vegetations using a m

124 e the entire treatment arc including pre-HCT debulking, possibly with hypomethylating agents, conditi

125 ly, the presence of ALDH(+)CD133(+) cells in debulked primary tumor specimens correlated with reduced

126 sions in the group of patients who underwent debulking prior to stenting.

127 ore was 90 (range, 70 to 100), and 77% had a debulking procedure.

128 dical therapy, and patients require repeated debulking procedures to maintain voice and airway functi

129 7 and January 2020, 39 patients underwent 41 debulking procedures with power assisted liposuction, in

130 herapy have prolonged overall survival after debulking procedures.

131 A comprehensive, multi-disciplinary debulking program can be successfully implemented in the

132 s; however, none required further surgery to debulk radiation necrosis.

133 Treatment regimens include debulking, radiotherapy with IP radioisotopes, and chemo

134 oyment with and without lesion modification (debulking) results in a favorable in-hospital outcome, w

135 Cosmetic blepharoplasty with fat pad debulking should be performed at least 6 months prior to

136 of this approach in patients with optimally debulked stage III ovarian cancer.

137 improves survival in patients with optimally debulked stage III ovarian cancer.

138 n, and IV paclitaxel in women with optimally debulked, stage III ovarian cancer.

139 ontrolling for clinical parameters including debulking status and age (multivariate analysis p = 0.00

140 iables such as age, stage, grade, histology, debulking status and response to chemotherapy continue t

141 Preoperative CA-125 level, debulking status, and ascites were also significant surv

142 at surgery, preoperative serum CA-125 level, debulking status, and ascites, moderate-to-large pleural

143 When adjusted for age, stage, and debulking status, the score predicted progression-free s

144 ostic factors such as age, stage, grade, and debulking status.

145 ll resected tumors were derived from routine debulking surgeries.

146 1), more had zero residual disease following debulking surgery (119 [46%] vs 157 [30%]; p<0.0001), an

147 ajor postoperative complications (P < .001), debulking surgery (CCR 2 or 3; P < .001), prior chemothe

148 8), high peritoneal cancer index (P = .013), debulking surgery (completeness of cytoreduction [CCR],

149 Interval debulking surgery (IDS) was required after cycle 3.

150 a malignancy before undergoing primary HGSC debulking surgery (n = 14) or patients at disease recurr

151 ric disease, outcomes are comparable between debulking surgery alone, immunochemotherapy alone, or a

152 -FES PET was in accordance with histology at debulking surgery but not at primary diagnosis, indicati

153 iform, with some patients undergoing primary debulking surgery followed by chemotherapy (PDS) and oth

154 Debulking surgery for an invasive GH-secreting adenoma i

155 d toxicity and by the low 2.5% prevalence of debulking surgery for symptomatic radiation necrosis.

156 r platinum-based chemotherapy, with interval debulking surgery in cohort one.

157 The role of debulking surgery in human immunodeficiency virus (-) MC

158 At referral, all patients underwent debulking surgery of the inflammatory lacrimal gland mas

159 he likelihood of complete resection although debulking surgery often is believed to be useful in pati

160 nced ovarian cancer, patients should undergo debulking surgery or chemotherapy to achieve a minimal d

161 aring large tumors with 5 mg/kg/d SM16 after debulking surgery reduced the extent of tumor recurrence

162 epithelial ovarian cancer who had undergone debulking surgery to receive one of three treatments.

163 ptide receptor radionuclide therapy and from debulking surgery to systemic therapy.

164 elial ovarian cancer were treated (following debulking surgery) with paclitaxel as a 3-hour infusion

165 At 2 months after the debulking surgery, a full clinical recovery was seen in

166 nal hazards model were a history of previous debulking surgery, absence of deep tissue invasion, mini

167 in cohorts treated with primary or interval debulking surgery, according to the surgery completeness

168 tology available at primary diagnosis and at debulking surgery, immunohistochemical ERalpha expressio

169 primary debulking surgery, n = 700; interval debulking surgery, n = 154).

170 140 enrolled patients were analyzed (primary debulking surgery, n = 700; interval debulking surgery,

171 lopian tube, or peritoneal cancer (following debulking surgery, or candidates for neoadjuvant chemoth

172 Among patients who underwent interval debulking surgery, the rate was 39.7% (95% CI, 27.0 to 5

173 s ovarian cancer before their standard tumor debulking surgery.

174 ids persisting in the peritoneal fluid after debulking surgery.

175 d with neoadjuvant chemotherapy and interval debulking surgery.

176 A resective or debulking surgical approach was described in 77.0% of al

177 rian cancer patients who have been optimally debulked survive longer.

178 dy we describe our experience implementing a debulking technique from Sweden in the United States.

179 Nevertheless, utilization of stenting and debulking techniques improves immediate and long-term ou

180 Debulking techniques may allow the optimal deployment of

181 aditionally, surgical treatment consisted of debulking that was repeated until no further benefit cou

182 , 2009, after a surgical procedure aiming to debulk the disease, women with International Federation

183 n activated thiopropyl resin was employed to debulk the tissue extract by selectively removing a subs

184 ntervention with the intent to cure (90%) or debulk the tumor (9%).

185 Cost-effective methods to debulk the virus in the oral cavity may aid in the preve

186 mer-docetaxel conjugate (P-DTX) effective in debulking the tumor mass.

187 tive endocarditis who underwent percutaneous debulking, the average age was 41.3+/-10.1 years, all pa

188 s the T cell pool needed for immediate tumor debulking, the infused T cells generally have a narrow r

189 difficult-to-treat gout as induction and/or debulking therapy (that is, for lowering of the urate po

190 lar mutation burden, indicating that surgery debulks these cancers physically but not molecularly.

191 could be used to allow microscopic surgical debulking to assure maximal surgical effort.

192 e experience has shown that optimum surgical debulking to leave residual tumour deposits that are les

193 with survival in optimally and suboptimally debulked tumor sets at a P value of <0.01.

194 d symptomatic treatment is based on surgical debulking, tumor embolization, and biotherapy with somat

195 ognostic classifier defined for suboptimally debulked tumors may aid in the classification and enhanc

196 sion profiles of advanced stage suboptimally debulked tumors.

197 ining VS-5584 with classic chemotherapy that debulks tumors may engender a more effective strategy to

198 Cytotoxic chemotherapy is effective in debulking tumour masses initially; however, in some pati

199 ntraoperative MRI from initial resection and debulking until death (median age at initial resection,

200 ediate angiographic and long-term results of debulking versus balloon angioplasty for treatment of tr

201 Aggressive surgical debulking, very close observation of the course of disea

202 To advance a novel concept of debulking virus in the oral cavity, the primary site of

203 Second, optimal debulking was associated with increased PFS mainly for p

204 Recurrence of the tumor after debulking was monitored.

205 shed data on surgical outcomes, percutaneous debulking was noninferior and superior for the composite

206 fluorescence surgery for tumor debulking, wide local excision, whole-organ resection, a

207 labrutinib, and venetoclax after an optional debulking with bendamustine regimen requires further eva

208 labrutinib, and venetoclax after an optional debulking with bendamustine.

209 Debulking with excimer laser or atherectomy was performe

210 Plaque debulking with lasing before PTCA may result in improved

211 Debulking with power assisted liposuction is an effectiv

212 For debulking with power assisted liposuction, the surgical

213 Tissue debulking with RA yielded better results only in diabeti

214 analyses confirmed the importance of optimal debulking with regard to PFS (debulking optimal v subopt

215 uates a sequential treatment consisting of a debulking with two cycles of bendamustine for patients w

216 e branch) with conventional PTCA (n = 30) or debulking (with rotational or directional atherectomy) p